Global Point-of-Care Molecular Diagnostics Market Strategic Research Report

The global point-of-care (POC) molecular diagnostics market has emerged as one of the most consequential segments within the broader in-vitro diagnostics industry, valued at approximately USD 8.4 billion in 2024. This market encompasses rapid nucleic acid amplification technologies — including PCR, isothermal amplification, and CRISPR-based assays — deployed at or near the patient site rather than centralized clinical laboratories. The significance of this segment extends well beyond clinical convenience: POC molecular diagnostics directly compresses the time from sample collection to actionable clinical decision, a factor that has proven decisive in managing infectious disease outbreaks, antimicrobial stewardship programs, and chronic disease monitoring in resource-limited settings. The COVID-19 pandemic fundamentally restructured the investment landscape, permanently expanding infrastructure, regulatory pathways, and clinician familiarity with near-patient molecular testing. Healthcare systems across North America, Europe, and Asia Pacific have since retained — and in many cases expanded — decentralized testing capabilities, embedding POC molecular diagnostics as standard-of-care infrastructure rather than an emergency contingency.

Three principal forces are propelling market expansion through the forecast period. First, the rising global burden of respiratory infections, sexually transmitted infections, and antimicrobial-resistant pathogens is generating sustained demand for rapid, definitive pathogen identification at the point of care; clinicians increasingly require same-visit results to prescribe targeted therapies and avoid empirical antibiotic overuse. Second, continued miniaturization of real-time PCR and loop-mediated isothermal amplification (LAMP) platforms — combined with cartridge-based, sample-to-answer workflow automation — has substantially reduced the technical expertise required to operate these systems, enabling deployment in physician offices, pharmacies, urgent care centers, and low-resource clinics. Third, regulatory modernization in the United States (FDA CLIA waiver expansion), the European Union (IVDR implementation driving quality standardization), and emerging markets is accelerating the commercial pathway for novel assays. A meaningful restraint, however, is the persistently elevated cost per test relative to immunoassay-based rapid diagnostics, which limits adoption in price-sensitive healthcare environments and among payers who question the incremental clinical value over less expensive alternatives.

This report provides a comprehensive, independently verified analysis of the global POC molecular diagnostics market across the 2025–2032 forecast period, with a historical baseline extending to 2019. Coverage spans product type segmentation, end-use application analysis, regional and country-level forecasts across 46 geographies, competitive profiling of ten major market participants, and structured frameworks including PESTLE, SWOT, and Porter's Five Forces. The report is designed primarily for corporate strategy teams evaluating portfolio positioning, investment analysts conducting sector due diligence, M&A advisors assessing acquisition targets, and procurement managers benchmarking technology platforms for institutional deployment.